Clinical trials: RSV
Bronchiolitis, Infection
Exhaled Nitric Oxide Levels in Infants and Young Children Infected With RSV or Other Viral Infections
The fraction of exhaled nitric oxide (FeNO) in expired air is a reliable measure of airway inflammation and has been used as a marker in asthma and other respiratory illnesses such as primary ciliary dyskinesia, bronchopulmonary…
- Conditions
- Bronchiolitis, Infection, Nitric Oxide
- Trial name
- NCT01098227
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- NYU Langone Health
Respiratory Syncytial Virus Infections
Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in Infants and Children
Human respiratory syncytial virus (RSV) is a common cause of respiratory illness in infants and children around the world. This study will evaluate the safety and immune response to a RSV vaccine in three groups of participants…
- Trial name
- NCT01893554
- Testing
- RSV ΔNS2 Δ1313 I1314L Vaccine
- Where
- 2 sites in United States
- Volunteers
- 88 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cancer
Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation
RATIONALE: Antivirals such as ribavirin are used to treat infections caused by viruses. It is not yet known if ribavirin is more effective with or without monoclonal antibody therapy in treating patients who develop RSV pneumonia…
- Trial name
- NCT00014391
- Testing
- palivizumab, ribavirin
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Infections, Respiratory Syncytial Virus
Study to Evaluate the Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccines
The purpose of this first time in human (FTiH) study is to evaluate the safety, reactogenicity and immunogenicity of several formulations of Respiratory Syncytial Virus (RSV) investigational vaccines in healthy men.
- Trial name
- NCT01905215
- Testing
- RSV vaccine GSK3003892A (formulation 1), RSV vaccine GSK3003893A (formulation 2), RSV vaccine GSK3003895A (formulation 3)
- Where
- 3 sites in Canada
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bronchiolitis
Association of Dysbiosis and Immune Response in Bronchiolitis in Under 12 Months -Old Infants
Acute bronchiolitis is a common disease in children under the age of two, caused mainly by the respiratory syncytial virus (RSV).
- Trial name
- BRONCHOBIOTE (NCT06161285)
- Testing
- Sampling
- Where
- 3 sites in France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
RSV Infection
Safety and Immunogenicity Study of Revaccination With SCB-1019T in Healthy Adults
CLO-SCB-1019-002 is the first study of SCB-1019T vaccine for revaccination in older adults who were previously vaccinated with AREXVY. The safety, tolerability and immunogenicity of SCB-1019T are assessed.
- Trial name
- NCT06843317
- Testing
- Candidate vaccine, SCB-1019T, AREXVY
- Where
- 5 sites in United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals USA, LLC
Respiratory Syncytial Virus Infections
Safety Study of Oral BTA9881 to Treat RSV Infection
This is a placebo-controlled, double-blind, randomised, single dose escalation Phase I clinical trial to determine the safety and tolerability of BTA9881 administered orally to healthy subjects
- Trial name
- NCT00504907
- Testing
- BTA9881
- Where
- Australia
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Biota Scientific Management Pty Ltd
Respiratory Syncytial Virus Infections
Study of Single and Multiple Doses of ALS-008176 in Healthy Volunteers
This study will assess the safety, tolerability, and pharmacokinetics (PK) of orally administered ALS-008176 in healthy volunteers.
- Trial name
- NCT01906164
- Testing
- ALS-008176
- Where
- France
- Volunteers
- 101 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Influenza Viruses, Respiratory Syncytial Virus (RSV)
ELderly REspiratory VIral Cohort
In addition to SarsCov2, the main viral respiratory risks are associated with influenza viruses, respiratory syncytial virus (RSV), human metapneumovirus (hMPV) parainfluenza virus (PIV), adenovirus, rhinovirus, coronavirus and…
- Conditions
- Influenza Viruses, Respiratory Syncytial Virus (RSV), Severe Acute Respiratory Syndrome Coronavirus 2, Human Metapneumovirus (hMPV)
- Trial name
- ELREVI (NCT07813481)
- Testing
- Respiratory viral infection
- Volunteers
- 1,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
RSV Infection, Bronchiolitis
Evaluation of Lung Ultrasonography Findings in Newborns With Respiratory Syncytial Virus Bronchiolitis
Respiratory Syncytial Virus (RSV) is a seasonal, highly contagious pathogen belonging to the Pneumoviridae (genus orthopneumovirus), a family of negative-strand RNA viruses.
- Trial name
- NCT06204367
- Testing
- Lung Ultrasonografisi
- Where
- Turkey (Türkiye)
- Volunteers
- 28 people
- Sponsor
- Kırıkkale University
-Unhealthy Children With a History of Prematurity
A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)
A total of 150 children who meet the entry criteria will be randomized 1:1 to receive one of the following treatment sequence A or B.
- Trial name
- NCT00240929
- Testing
- MEDI-493
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- MedImmune LLC
Older Adults Without Any Specific Clinical Condition, Social Networks
A Study to Evaluate Community-Based Measures to Increase RSV Vaccine Use Among Latino Adults
In collaboration with community-based organizations, this study will focus on increasing RSV vaccine use among Latinos. The study will determine how effective community health worker counseling and text-message approaches are to…
- Conditions
- Older Adults Without Any Specific Clinical Condition, Social Networks, RSV Immunization, Vaccine Uptake
- Trial name
- NCT07171164
- Testing
- Motivate Aim: CHW text message reminders and counseling, Motivate Aim: CHW text message reminders only, Activate Aim: CHW text message reminders and counseling
- Where
- United States
- Volunteers
- 750 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
COVID-19, SARS-CoV-2 Infection, RSV
Clinical Outcomes and Pharmacotherapy Effectiveness in the VA Health Care System (COPE-VA)
The purpose of this study is to comprehensively describe the temporal and geographic utilization of COVID-19 therapies used for mild to moderate disease during different periods of SARS-CoV-2 variant circulation as well as to…
- Conditions
- COVID-19, SARS-CoV-2 Infection, RSV, Influenza
- Trial name
- COPE-VA (NCT06160128)
- Where
- United States
- Volunteers
- 400,000 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Respiratory Tract Infection, Respiratory Syncytial Virus
Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and incidence of anti-drug antibodies (ADAs) of single ascending doses of clesrovimab in healthy pre-term (born at 29 to 35 weeks gestational…
- Trial name
- NCT03524118
- Testing
- Clesrovimab
- Where
- 34 sites in United States, Chile and 4 more
- Volunteers
- 183 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Bronchiolitis, Viral
Effectiveness of Nirsevimab in Children Hospitalised With RSV Bronchiolitis
Respiratory tract infections caused by respiratory syncytial virus (RSV) are a worldwide burden and represent a major public health issue.
- Trial name
- ENVIE (NCT06030505)
- Testing
- No intervention required by the protocol
- Where
- 5 sites in France
- Volunteers
- 1,140 people
- Sponsor
- Centre Hospitalier Intercommunal Creteil
RSV Infection
Epidemiological and Clinical Characteristics of Hospitalized Patients Under 5 Years Old With RSV Infection in Central China, Wuhan
The study will be a multicenter, hospital-based retrospective study. We plan to collect the clinical and laboratory data among all hospitalized ARTI cases in three hospitals in Wuhan from June 1, 2020 to May 31, 2023 and then…
- Trial name
- NCT05767294
- Testing
- Observation
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Tongji Hospital
Respiratory Syncytial Virus, Respiratory Tract Diseases
Impact and Effectiveness of ABRYSVO® Vaccination During Pregnancy
This study will be conducted in collaboration with a research network of independent hospital sites to evaluate the vaccine effectiveness (VE) and impact of ABRYSVO vaccination during pregnancy in a real-world population over…
- Trial name
- BERNI (NCT06647654)
- Testing
- ABRYSVO
- Where
- Argentina
- Volunteers
- 1 people
- Sponsor
- Pfizer
Respiratory Infections, Acute, Respiratory Syncytial Virus
RSV Disease in the Elderly
Respiratory syncytial virus (RSV) causes sickness and deaths in older people every winter. This study will investigate how aging affects the body's immune response (body's response to disease) to RSV.
- Trial name
- NCT00246480
- Where
- United States
- Volunteers
- 1,401 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pharmacokinetics, Healthy Volunteers
Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers
This is a single center, sequential-cohort, double-blind, placebo-controlled, multiple ascending dose (MAD), 7-day treatment period study in healthy subjects.
- Trial name
- NCT02668367
- Testing
- BTA-C585 oral capsules
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Biota Pharmaceuticals, Inc.
Respiratory Syncytial Virus
BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study)
The primary objectives of the study are: To estimate the effectiveness of nirsevimab against polymerase chain reaction (PCR)-confirmed RSV (1) lower respiratory tract (LRTD) and (2) related medical encounters.
- Trial name
- BEAR (NCT06325332)
- Testing
- Nirsevimab
- Where
- United States
- Volunteers
- 49,680 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company